Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.

Autor: Kaur A; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Rojek AE; Hematology/Oncology Department of Medicine, University of Chicago Medicine, Chicago, IL, USA., Symes E; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Nawas MT; Hematology/Oncology Department of Medicine, University of Chicago Medicine, Chicago, IL, USA., Patel AA; Hematology/Oncology Department of Medicine, University of Chicago Medicine, Chicago, IL, USA., Patel JL; Departments of Pathology and Hematology/Oncology, University of Utah/ARUP, Salt Lake City, UT, USA., Sojitra P; Department of Pathology, Rutgers Robert Wood Johnson Medical School New Brunswick NJ, New Brunswick, NJ, USA., Aqil B; Department of Pathology, Northwestern Memorial Hospital, Chicago, IL, USA., Sukhanova M; Department of Pathology, Northwestern Memorial Hospital, Chicago, IL, USA., McNerney ME; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Wu LP; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Akmatbekov A; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Segal J; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Tjota MY; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Gurbuxani S; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Cheng JX; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Yeon SY; Department of Pathology, University of Illinois, Chicago, IL, USA., Ravisankar HV; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Fitzpatrick C; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Lager A; Hematology/Oncology Department of Medicine, University of Chicago Medicine, Chicago, IL, USA., Drazer MW; Hematology/Oncology Department of Medicine, University of Chicago Medicine, Chicago, IL, USA., Saygin C; Hematology/Oncology Department of Medicine, University of Chicago Medicine, Chicago, IL, USA., Wanjari P; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Katsonis P; Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA., Lichtarge O; Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA., Churpek JE; Division of Hematology, Department of Medicine, University of Wisconsin, Madison, WI, USA., Ghosh SB; Department of Pathology, Henry Ford Health Systems, Detroit, MI, USA., Patel AB; Departments of Pathology and Hematology/Oncology, University of Utah/ARUP, Salt Lake City, UT, USA., Menon MP; Departments of Pathology and Hematology/Oncology, University of Utah/ARUP, Salt Lake City, UT, USA., Arber DA; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Wang P; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA., Venkataraman G; Department of Pathology, Sections of Hematopathology and Genomic Pathology, University of Chicago Medicine, Chicago, IL, USA. girish.venkataraman@uchospitals.edu.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Jun 18; Vol. 14 (1), pp. 99. Date of Electronic Publication: 2024 Jun 18.